Table 2.
Changes in Scr and eGFR
| Characteristics | Basic treatment Group (n=51) | Standard CS therapy Group (n=49) | Intensive CS therapy Group (n=50) |
|---|---|---|---|
| Baseline Scr (μmol/L) | 83.2±18.6 | 82.8±19.2 | 83.4±19.5 |
| Day 1 after PCI (μmol/L) | 91.4±18.8a | 90.5±17.9a | 88.8±19.2a,c |
| Day 2 after PCI (μmol/L) | 98.5±20.2b | 96.8±19.2b | 91.3±18.6b,c,e |
| Day 3 after PCI (μmol/L) | 87.6±17.7 | 86.7±16.8 | 84.6±17.8 |
| Baseline eGFR (ml/min/1.73m2) | 119.8±5.6 | 120.4±5.7 | 121.7±6.4 |
| Day 1 after PCI (ml/min/1.73m2) | 111.3±6.4a | 113.2±6.7a | 115.7±6.3a,c |
| Day 2 after PCI (ml/min/1.73m2) | 105.4±6.5b | 107.5±7.2b | 110.1±6.9b,c,e |
| Day 3 after PCI (ml/min/1.73m2) | 117.7±5.9 | 118.9±6.4 | 119.2±6.2 |
| eGFR >25% decrease [n (%)] | 7 (13.73) | 5 (10.2)c | 4 (8.0)d |
| Incidence of CIN [n (%)] | 6 (11.76) | 4 (8.16)c | 3 (6.0)d |
a
compared to baseline, P<0.05;
b
compared to baseline, P<0.01;
c
compared to basictreatment group, P<0.05;
d
compared to basic treatment group, P<0.01;
e
compared to Standard CS therapy group, P<0.05.